NUVL - Nuvalent announces $300M offering of Class A common stock
2023-10-16 08:16:09 ET
More on Nuvalent
- Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip
- Nuvalent's drug shows promise in lung cancer patients in preliminary phase 1 data
- Nuvalent surges on Phase 1 data for lung cancer therapy
- Seeking Alpha’s Quant Rating on Nuvalent
- Historical earnings data for Nuvalent
For further details see:
Nuvalent announces $300M offering of Class A common stock